The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
Open accessAbstract
The HER2 gene encodes a cell-surface glycoprotein with extensive homology to the epidermal growth factor receptor. Recently it was found to be amplified in about 30% of primary human breast malignancies. In experiments designed to assess the role of the HER2 gene in oncogenesis, we found that overexpression of unaltered HER2 coding sequences in NIH 3T3 cells resulted in cellular transformation and tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationA new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationCoussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citationSherr, C. J., Rettenmier, C. W., Sacca, R., Roussel, M. F., Look, A. T., & Stanley, E. R. (1985) · Cell · doi:10.1016/s0092-8674(85)80047-7 · Cited by 1,540
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Self-citationAmplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Alt, F. W., Kellems, R. E., Bertino, J. R., & Schimke, R. T. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34875-5 · Cited by 941
Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., & Berger, W. H. (1987) · PubMed · Cited by 898
Self-citation
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationSignal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Identification of Heregulin, a Specific Activator of p185 erbB2
Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., et al. (1992) · Science · doi:10.1126/science.256.5060.1205 · Cited by 962
Specificity within the EGF family/ErbB receptor family signaling network
Riese, D. J., & Stern, D. F. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v · Cited by 809
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Self-citationEwer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Self-citationXia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Self-citationWen, D., Peles, E., Cupples, R., Suggs, S. V., Bacus, S. S., Luo, Y., Trail, G., Hu, S., Silbiger, S. M., Levy, R. B., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90456-m · Cited by 577
HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574
Self-citationBiochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., & Yarden, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90131-u · Cited by 524
“Consistent with these observations, ectopic overexpression of neul HER-2 can transform rodent fibroblasts (Di Fiore et al., 1987; Hudziak et al., 1987).”
BackgroundPantel, K., Schlimok, G., Braun, S., Kutter, D., Lindemann, F., Schaller, G., Funke, I., Izbicki, J. R., & Riethmuller, G. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1419 · Cited by 503
Sher, T., Dy, G. K., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.355 · Cited by 498
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 436
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Self-citationSelective in vivo metabolic cell-labeling-mediated cancer targeting
Wang, H., Wang, R., Cai, K., He, H., Liu, Y., Yen, J., Wang, Z., Xu, M., Sun, Y., Zhou, X., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2297 · Cited by 386
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Xu, W., Mimnaugh, E., Rosser, M. F. N., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006864200 · Cited by 353
RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts.
Cook, S. J., Rubinfeld, B., Albert, I., & McCormick, F. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06022.x · Cited by 349
Vitanza, N. A., Johnson, A. J., Wilson, A. L., Brown, C., Yokoyama, J. K., Künkele, A., Chang, C. A., Rawlings-Rhea, S., Huang, W., Seidel, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01404-8 · Cited by 321
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., & Vande Woude, G. F. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5152 · Cited by 312
Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., & Greene, M. I. (1989) · Cell · doi:10.1016/0092-8674(89)90843-x · Cited by 309
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
Self-citationTrastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2
McKeage, K., & Perry, C. M. (2002) · Drugs · doi:10.2165/00003495-200262010-00008 · Cited by 289
Neu and its ligands: From an oncogene to neural factors
Peles, E., & Yarden, Y. (1993) · BioEssays · doi:10.1002/bies.950151207 · Cited by 279
The epidermal growth factor receptor as a multifunctional allosteric protein
Schlessinger, J. (1988) · Biochemistry · doi:10.1021/bi00409a002 · Cited by 279
Self-citationHER2 as a Prognostic Factor in Breast Cancer
Ménard, S., Fortis, S., Castiglioni, F., Agresti, R., & Balsari, A. (2001) · Oncology · doi:10.1159/000055404 · Cited by 268
Menendez, J. A., Vellon, L., Colomer, R., & Lupu, R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi090 · Cited by 263
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer
Reese, D. M., & Slamon, D. J. (1997) · STEM CELLS · doi:10.1002/stem.150001 · Cited by 229
Gandhi, L., Bahleda, R., Tolaney, S. M., Kwak, E. L., Cleary, J. M., Pandya, S. S., Hollebecque, A., Abbas, R., Ananthakrishnan, R., Berkenblit, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2787 · Cited by 198
Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Overexpression of the c-erbB-2 protein in human breast tumor cell lines
Hynes, N. E., Gerber, H. A., Saurer, S., & Groner, B. (1989) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240390208 · Cited by 109
Johanning, F. W., Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L. A., Pike, M. J., & Curiel, D. T. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.9.1495 · Cited by 99
Hingorani, P., Zhang, W., Zhang, Z., Xu, Z., Wang, W.-L., Roth, M. E., Wang, Y., Gill, J. B., Harrison, D. J., Teicher, B. A., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0758 · Cited by 28
Metadata
- Authors
- Hudziak, R. M., Schlessinger, J., & Ullrich, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1987-10
- Volume
- 84
- Issue
- 20
- Pages
- 7159-7163
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1966823692
- Cited by
- 625
- References
- 27
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.